MoonLake ImmunotherapeuticsMLTX
MLTX
About: MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Employees: 100
0
Funds holding %
of 7,202 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
141% more call options, than puts
Call options by funds: $21.1M | Put options by funds: $8.78M
131% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 16
17% more funds holding
Funds holding: 115 [Q4 2024] → 134 (+19) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]
5.98% less ownership
Funds ownership: 100.57% [Q4 2024] → 94.58% (-5.98%) [Q1 2025]
29% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 42
32% less capital invested
Capital invested by funds: $3.43B [Q4 2024] → $2.34B (-$1.1B) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$61
56%
upside
Avg. target
$73
87%
upside
High target
$100
155%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Wolfe Research Andy Chen | 56%upside $61 | Outperform Upgraded | 19 May 2025 |
Needham Serge Belanger | 68%upside $66 | Buy Reiterated | 13 May 2025 |
RBC Capital Brian Abrahams | 71%upside $67 | Outperform Initiated | 18 Mar 2025 |
Goldman Sachs Richard Law | 86%upside $73 | Buy Maintained | 27 Feb 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 155%upside $100 | Buy Reiterated | 27 Feb 2025 |
Financial journalist opinion
Based on 3 articles about MLTX published over the past 30 days
Positive
Zacks Investment Research
4 days ago
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet
The consensus price target hints at a 106.6% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 week ago
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody ® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA) Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trial Presented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab in an indication with currently no approved therapeutics in the US and Europe, and further derisking the overall development of sonelokimab Ended the first quarter with $480.1 million in cash, cash equivalents and short-term marketable debt securities and announced closing of a debt facility, providing up to $500 million in non-dilutive funds and extending expected cash runway into 2028 ZUG, Switzerland, May 12, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the first quarter of 2025. Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics, said: “We continue executing across our portfolio of indications with quality, speed and efficiency.
Neutral
GlobeNewsWire
3 weeks ago
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a virtual Capital Markets Day for investors and analysts on Tuesday, April 29, 2025. The event will highlight recent financial and clinical milestones and provide future strategic updates.
Positive
Seeking Alpha
1 month ago
MoonLake Immunotherapeutics: A Buy At Dips
MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials, yet faced a significant stock drop due to institutional sell-offs. Despite mixed results from the ARGO study, sonelokimab demonstrated superior efficacy against Humira and Secukinumab, indicating strong potential for future success. Institutional sell-offs in late 2023 caused a drastic stock decline, but MLTX remains financially stable with a cash runway extending into 2027.
Neutral
GlobeNewsWire
1 month ago
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets, for up to $500 million in non-dilutive capital, of which $75 million drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake's strategy and funding needs.
Neutral
GlobeNewsWire
2 months ago
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
ZUG, Switzerland, February 26, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced its financial results for the fourth quarter and year ended December 31, 2024.
Positive
Seeking Alpha
4 months ago
MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon
MoonLake Immunotherapeutics is set to release results from both the phase 3 VELA-1 and VELA-2 studies using sonelokimab to target moderate-to-severe Hidradenitis Suppurativa patients in mid-2025. The unique nanobody structure of sonelokimab, binding to three IL-17 dimers, positions it as a potential best-in-class IL-17 inhibitor. Positive data from VELA-1, VELA-2, and VELA-TEEN studies could lead to a single BLA filing for sonelokimab, enhancing shareholder value.
Neutral
GlobeNewsWire
4 months ago
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA) MoonLake now independently running seven trials in 2025 across large dermatology and rheumatology indications: adult HS, adolescent HS, psoriatic arthritis (PsA), PPP and axSpA Phase 2 and Phase 3 data read-outs across all target indications expected in 2025 (adult HS, and PPP) and 2026 (adolescent HS, PsA and axSpA) Data from the Phase 3 VELA-TEEN trial may be combined with the Phase 3 VELA program in adults with moderate-to-severe HS to support the first Biologics License Application (BLA) for the Nanobody® sonelokimab Zug, Switzerland, January 8, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that patients have been screened in three new trials across three new indications to evaluate sonelokimab, an investigational Nanobody® designed to treat inflammatory disease. The clinical program for sonelokimab now includes patients with adolescent hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA), in addition to adult patients with HS and active psoriatic arthritis (PsA).
Neutral
GlobeNewsWire
8 months ago
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from 2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CET The event will provide business updates from MoonLake's CEO Jorge Santos da Silva, CSO Kristian Reich and CFO Matthias Bodenstedt and include details on the Phase 3 programs for our investigational Nanobody® sonelokimab (SLK) in hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). In addition, MoonLake will provide pipeline updates and details on additional catalysts for the 2024-2026 period, including for trials in new indications such as the Phase 2 trials of SLK in palmo-plantar pustulosis (PPP).
Positive
Seeking Alpha
10 months ago
MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 2026. The global hidradenitis suppurativa market is expected to reach $1 billion by 2029. The initiation of the IZAR program, using sonelokimab for patients with Psoriatic Arthritis, is expected to launch in Q4 of 2024; Primary endpoint data is expected at the end of 2026.
Charts implemented using Lightweight Charts™